OPEN Regional Meeting June 26 and June 27, 2015 Hyatt ...

Friday, June 26 OPEN Regional Meeting
June 26 and June 27, 2015
10:00 am - 10:45 am
10:45 am - 11:00 am Hyatt Regency Pier Sixty Six
11:00 am - 12:00 pm 2301 Southeast 17th Street
Fort Lauderdale, Florida, 33316
12:00 pm - 1:00 pm
1:00 pm - 2:00 pm AGENDA

Registration; Breakfast in the Exhibitor Pavilion

Introduction and Welcome

Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents
Patrick J. Medina, PharmD, BCOP
University of Oklahoma College of Pharmacy
Review the impact the pathophysiology of RCC has on the choice of drug therapy
in both the adjuvant and metastatic treatment of renal cell cancers. A review of
trial design and preliminary data (if available) of targeted agents used in the
adjuvant setting will be presented. Data reviewing both FDA approved
indications, and comparisons between targeted agents, used for metastatic RCC
will also be presented. Finally, drug monitoring parameters and potential markers
of response will be evaluated. Application Based. Activity Number: 0280-9999-15-
011-L01-P. CE Hours: 1.0

Objectives
 Outline the pathophysiology of RCC and how this impacts drug selection.
 Review the use of targeted agents in the adjuvant treatment of RCC.
 Analyze the trial data to make appropriate first-line treatment

recommendations for metastatic RCC.
 Given patient specific information select appropriate medications to treat

metastatic RCC; including the appropriate sequencing of agent for patients
who have progressed on initial therapy.
 Describe the mechanism of action, adverse reactions, and monitoring
parameters of targeted agents used to treat RCC.

Lunch in the Exhibitor Pavilion

Novel Therapeutic Options for Non-Hodgkin Lymphoma
Christopher A. Fausel, PharmD, MHA, BCOP
Indiana University Simon Cancer Center
Identify a number of advances in treating various histopathologic subtypes on
non-Hodgkin lymphoma. Emphasis will be placed on the incorporation of targeted

2:00 pm - 2:15 pm therapy agents either alone or in combination with standard cytotoxic agents.
2:15 pm - 3:15 pm Primary literature will be reviewed for first-line and salvage therapy for the most
common histopathologic subtypes of non-Hodgkin lymphoma and appropriate
3:15 pm - 3:45 pm supportive care measure for these treatments will be highlighted. Application
3:45 pm - 4:45 pm Based. Activity Number: 0280-9999-15-012-L01-P. CE Hours: 1.0

4:45 pm - 5:00 pm Objectives
5:00 pm - 6:00 pm  Review historical treatment regimens for non-Hodgkin lymphoma and the

evidence supporting their use.
 Delineate emerging therapies into the treatment paradigm of non-Hodgkin

lymphoma across multiple histopathologic subtypes.
 Describe how pharmacists can ensure appropriate supportive care for

patients during treatment for non-Hodgkin lymphoma.

Refreshments in the Exhibitor Pavilion

Case Studies in Multiple Myeloma: Integrating Novel Agents into Practice
R. Donald Harvey, PharmD, FCCP, BCOP
Winship Cancer Institute of Emory University
Gain knowledge on treatment advances in multiple myeloma. Participants will
evaluate the safety and efficacy results from recent clinical trials of emerging
treatments. There will be an opportunity to apply the trial data to patient cases to
optimize evidence based treatment. Application Based. Activity Number: 0280-
9999-15-013-L01-P. CE Hours: 1.0

Objectives
 Review the clinical manifestations and treatment advances in multiple

myeloma.
 Evaluate recently published clinical trial data on safety and efficacy of novel

treatments in multiple myeloma.
 Apply clinical trial information to specific patient cases for optimal evidence-

based treatment.

Refreshments in the Exhibitor Pavilion

Practical Issues with New Targeted Therapies for Cancer
Sarah L. Scarpace, PharmD, MPH, BCOP
Associate Professor, Albany College of Pharmacy
Review issues in the changing landscape for dispensing new agents and discuss
categories/ causes which can affect adherence such as (rems, specialty pharmacy
distribution, handling & storage, unique administration requirements) and
awareness of new or unrecognized drug interactions which can which will
negatively impact patient outcomes. Pharmacists will learn how they can help to
mitigate these potential barriers in order to optimize therapy. Application Based.
Activity Number: 0280-9999-15-014-L01-P. CE Hours: 1.0

Objectives
 Describe evidence-based consequences of non-adherence.
 Evaluate theoretical drug interactions for clinical significance.
 Recognize areas which can affect therapeutic outcomes such as handling &

storage, specialty pharmacy distribution, and unique administration
requirements.

Break

Biosimilars: Is This Really a Generic Vs Innovator Debate? (LAW)
Jim Koeller, MS
University of Texas at Austin

Saturday, June 27 Review the nuances of biosimilar regulation and development so that pharmacy
practitioners can make informed decisions about how to incorporate biosimilars
7:00 am - 7:30 am into the medication use process at their respective institutions. Application Based.
7:30 am - 8:30 am Activity Number: 0280-9999-15-015-L03-P. CE Hours: 1.0

8:40 am - 9:40 am Objectives
 Define biosimilars and explain recent federal regulations.
9:50 am - 10:50 am  Differentiate between biosimilars and interchangeable products.
 Describe what the pharmacist role should be in handling biosimilar and

interchangeable products.

Registration; Breakfast in the Exhibitor Pavilion

New Trends in the Management of Metastatic Breast Cancer
Chad Barnett, PharmD, BCOP
The University of Texas MD Anderson Cancer Center
Hear the most recent developments in treatments for metastatic breast cancer,
including new and emerging drugs. The presentation will address efficacy data
supporting use of the drugs as well as potential toxicities. Application Based.
Activity Number: 0280-9999-15-016-L01-P. 1.0 Credit Hours: 1.0

Objectives
 Evaluate the efficacy and toxicity of new pharmacological therapies for

management of patients with metastatic breast cancer.
 Analyze current data for new & emerging treatments of patients with

metastatic breast cancer.
 Discuss the management of adverse events associated with therapeutic agents

for patients with metastatic breast cancer.

GI Malignancies: An Update on Current Treatments
Trevor McKibbin, PharmD, MS, BCOP
Winship Cancer Institute of Emory University
Identify the current treatments and controversies regarding the treatment of
gastrointestinal malignancies, focusing on gastric and colon cancer. Application
Based. Activity Number: 0280-9999-15-017-L01-P. 1.0 Credit Hours: 1.0

Objectives
 Outline traditional and novel therapies in the treatment of colon and gastric

cancers including the benefits and limitations of each regimen.
 Develop a treatment plan for a patient with either colon cancer or gastric

cancer, using a given set of biomarkers.
 Discuss emerging therapies for the treatment of gastric and colorectal cancers.

Integrating Palliative Care in the Outpatient Setting
Suzanne Amato Nesbit, PharmD, BCPS, CPE
The Johns Hopkins Hospital
Gain insight on the importance of palliative care in improving the quality of life of
patients with cancer. Examine common barriers to implementing effective
palliative care practices with a focus on the emerging role of the pharmacist to
improve outcomes. Application Based. Activity Number: 0280-9999-15-018-L01-
P. Credit Hours: 1.0

Objectives
 Summarize the evidence supporting the significant impact of palliative care on

relevant outcomes.

11:00 am - 12:00 pm  Describe the barriers to implementing palliative care practices in outpatient
and private practice hematology/oncology settings.
12:00 pm - 1:00 pm
1:00 pm - 2:00 pm  Explain the emerging role of the pharmacist in promoting and optimizing
palliative services within the Vision for Comprehensive Cancer Care in 2020.
2:10 pm - 3:10 pm
Chronic Lymphocytic Leukemia (CLL): A Review of New and Emerging
Treatment Options
R. Donald Harvey, PharmD, FCCP, BCOP
Winship Cancer Institute of Emory University
There have been remarkable advances in our understanding of the biology and
therapeutics of chronic lymphocytic leukemia (CLL). Pharmacists need to
understand the current treatment recommendations and emerging therapeutics.
This program will help pharmacists make sense of the array of CLL treatment
options currently available and emerging. Application Based. Activity Number:
0280-9999-15-019-L01-P. Credit Hours: 1.0

Objectives
 Summarize current treatment options for the treatment of CLL, including

treatment outcomes and side effect profiles.
 Interpret new data on novel agents and therapeutic approaches with potential

importance in the treatment of patients with chronic lymphocytic leukemia.
 Review emerging treatment options for CLL.

Buffet Lunch in the Exhibitor Pavilion

Pharmacotherapy of Malignant Melanoma
Lew Iacovelli, BS, PharmD, BCOP, CPP
Cone Health Cancer Center
Several new agents have been approved by the FDA for the treatment of
melanoma, and recent clinical data indicate that additional agents are on the
horizon. This program will help pharmacists understand these new and emerging
therapies and how to optimally prevent and manage toxicities. Application Based.
Activity Number: 0280-9999-15-020-L01-P. Credit Hours: 1.0

Objectives
 Discuss the indications and use of recently approved agents used in the

treatment of melanoma.
 Illustrate methods for monitoring and managing toxicity in patients receiving

recently approved agents used in the treatment of melanoma.
 Appraise ongoing clinic trial data with these newer agents with respect to

their place as therapy options for patients with melanoma.

Update on Advanced Non-Small Cell Lung Cancer: Focus on Targeted
Therapies
Val R. Adams, PharmD, BCOP, FCCP
University of Kentucky College of Pharmacy
The treatment guidelines for NSCLC have been revised to optimize outcomes;
therapy recommendations are now directed by stage, histology, and genetic
mutational drivers. Pharmacists need to know how to incorporate changes to
therapy guidelines into practice. However, because many of the latest advances in
NSCLC care make use of targeted therapies, from which not all patients would
benefit, pharmacists also need to know which patients should receive which
therapy. This program will help pharmacists understand the role of targeted
therapies in the management of NSCLC. Application Based. Activity Number: 0280-
9999-15-021-L01-P. Credit Hours: 1.0

Objectives

 Recognize the therapeutic role for EGFR inhibitors, VEGF inhibitors, and PD1
inhibitors for advanced non-small cell lung cancer.

 Recommend appropriate toxicity prevention, monitoring, and treatment for
select novel agents in each therapeutic class.

 Identify targetable pathways where drug therapy is currently being
investigated.

3:20 pm - 4:20 pm Improving Compounding Practices while Protecting Healthcare Workers
Handling Hazardous Drugs (LAW)
Eric Kastango, MBA, RPh, FASHP
Clinical IQ, LLC
The national outbreak of the fungal meningitis from contaminated medication has
been a call to action to comply with the federally enforceable USP chapters on
compounding and their state pharmacy laws and regulations. Recently, USP
published a new chapter on the safe handling of hazardous drugs. Washington
State, California and Maryland have passed legislation designed to protect
healthcare workers handling hazardous drugs. This presentation will explore what
pharmacists will need to know to understand and comply with applicable rules
and regulations as it relates to compounding and occupational exposure to
hazardous drugs. Knowledge Based. Activity Number: 0280-9999-15-022-L03-P.
Credit Hours: 1.0

Objectives
 Describe the current regulatory environment for pharmacies that compound

sterile medications.
 Discuss the major proposed requirements of the new USP hazardous drug

chapter.
 Describe the various state and national initiatives designed to protect

healthcare workers handling hazardous drugs.
 Describe risk mitigation strategy to provide safe compounded medication

while protecting healthcare workers handling hazardous drugs.

*Agenda Subject to Change

Continuing Education

This programming has been designed to meet the educational needs of pharmacists, nurses and other interested
healthcare professionals specializing in hematology/oncology practice.

 Earn up to 12 Contact Hours (1.2 CEUs) - Includes 2 hours of Law Credits
 Sessions are individually accredited

Conference Objectives: Participants will be able to demonstrate clinical knowledge and ability to counsel patients in
the areas of: RCC, Non-Hodgkin Lymphoma, GI Malignancies, Breast Cancer, Compounding, Adherence, Multiple
Myeloma, Palliative Care, Chronic Lymphocytic Leukemia, Melanoma, NSCLC, and Biosimilars.

Pharmacists: American Health Resources, Inc. is accredited by the Accreditation Council for Pharmacy
Education as a provider of continuing pharmacy education.

Nurses: American Health Resources, Inc. is approved by the California Board of Registered Nursing, Provider # CEP
14254 and approved this program for 1.0 contact hour for each 1 hour session completed. Please check with
licensing board to verify credits can be claimed in your state.

Requirements for CE Credit

To receive credit participants must fully attend each session (no partial credit will be given) as well as pass in a
completed signature verification sheet; for pharmacists please include your NAPB e-profile number. Statements of
Credit will be issued to participants by logging onto www.AHRevents.com and completing the session evaluation

form for each session attended. Your continuing pharmacy education credit is automatically reported to CPE
Monitor. All participants will have the opportunity to evaluate the educational sessions and presenters as well as the
ability to identify their future educational needs.

Participants can earn Continuing Pharmacy Education credits for this program by going to www.ce.ahrevents.com
and completing the session evaluation form for session(s) attended within 60 days of session date. After completion
of the activity evaluation, your continuing pharmacy education credit is automatically reported to CPE Monitor
where a certificate of credit can be printed. Please allow up to 48 hours for credit to be available on the CPE Monitor.

Participant names will be checked against program attendance sheets for verification of attendance. Only Certificates
of Credit issued from CPE Monitor are valid in the U.S. CPE Monitor will not accept credits after 60 days from session
date. This meeting is registered with FL CE Broker: Provider # 50-4654-1, Course # 20-488705.

Registration and Pricing

ACCC Members: $95 (1 day) or $120 (2 days) ~ Discounted rates are $72/ $90

Non-ACCC members: $120 (1 day) or $150 (2 days) ~ Discounted rates are $90/$113

Take advantage of a 25% early bird rate until June 15!
Enter code FL25 at checkout.

Register at www.bitly.com/OPENFla

Hotel Information

For reservations at Hyatt Regency Pier Sixty Six, please call 954.525.6666 and mention the “Oncology
Pharmacy Education Network Meeting” to receive the discounted rate of $119.00/night (plus tax). The
group rate will be available until May 25, 2015, and is subject to availability. Outdoor valet parking is
$30/day, outdoor self parking is $25/day, and visitor valet parking is $11/day (plus 6% sales tax/day).

Questions?

Contact American Health Resources via email at [email protected] or call 508.588.7700

This OPEN meeting is supported by educational grants from:

Amgen Inc.
AstraZeneca
Boehringer Ingelheim Pharmaceuticals, Inc.
Bristol-Myers Squibb
Celgene Company
Hospira, Inc.

Lilly
Merck Sharp & Dohme Corp.

Novartis
Onyx Pharmaceuticals, an Amgen subsidiary

Takeda Oncology

This Oncology Pharmacy Education Network meeting is brought to you by: